Therapy Areas
INFECTIOUS DISEASE
We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and unknown infectious diseases. We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way. Allowing us to be at the forefront of patient response when it comes to infectious disease threats, affecting millions of people every year. We currently have five prophylactic vaccines in our development pipeline.
Meningitis ACYW135 Conjugate
IVIV 304
-
Platform
Conjugation
-
Market
The meningococcal vaccine market is diverse and complex with regional variations in serogroup distribution and significant use outside of routine immunization. The global supply of conjugate MenACWY is insufficient to meet demand growth triggered by rising incidence of serogroups C and W and the limited availability of polysaccharide vaccines. Low and middle income countries struggle for access to multivalent and conjugate vaccines due to limited global supply and high cost for conjugate vaccines. With this in consideration, our NMCV-4 program continues to be in development through self-funding.
Pentavalent Vaccine (DTaP-IPV-Hib)
IVIV 521
-
Platform
Conjugation
-
Market
The meningococcal vaccine market is diverse and complex with regional variations in serogroup distribution and significant use outside of routine immunization. The global supply of conjugate MenACWY is insufficient to meet demand growth triggered by rising incidence of serogroups C and W and the limited availability of polysaccharide vaccines. Low and middle income countries struggle for access to multivalent and conjugate vaccines due to limited global supply and high cost for conjugate vaccines. With this in consideration, our NMCV-4 program continues to be in development through self-funding.
-
Disease Protection
Pentavalent vaccine protects against five major diseases
- Diphtheria
- Tetanus
- Pertussis (Whooping Cough)
- Haemophilus Influenza Type B
- Polio
Hexavalent Vaccine (DTaP-IPV-Hib-HepB)
IVIV 859
-
Platform
Conjugation
-
Market
InventVacc is committed to supporting low-income countries with expectations of a higher quality of life
-
Disease Protection
Hexavalent vaccine protects against five major diseases
- Diphtheria
- Tetanus
- Pertussis (Whooping Cough)
- Haemophilus Influenza Type B
- Polio
- Hepatitis B
mRNA Vaccine
IVIV 391
-
Confidential
Confidential Information
mRNA Vaccine
IVIV 399
-
Confidential
Confidential Information
Multivalent pneumococcal vaccine –
PCV 25 Adult (Licensed product)
IVIV 433
-
Platform
Conjugation
-
Market
The value of the pneumococcal vaccines market will steadily grow over from USD 7.2 billion (2019) to over USD 11 billion by 2030 representing the second largest segment of the vaccine industry (measured by dollar volume).
IMMUNOTHERAPY
We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and future types of cancers. We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way. Allowing us to be at the forefront of patient response when it comes to cancer treatments, affecting millions of people every year.
HPV (high valency) Vaccine
IVIV 820
-
Platform
Conjugation
-
Market
Human papillomavirus infection (HPV infection) is an infection caused by human papillomavirus (HPV), a DNA virus from the Papillomaviridae family, Many HPV infections cause no symptoms, and 90% resolve within two years, however in some cases, an HPV infection persists and results in either warts or precancerous lesions. These lesions, depending on the site affected, increase the risk of cancer of the cervix, vulva, vagina, penis, anus, mouth, tonsils, or throat. Nearly all cervical cancer are due to HPV; two strains, HPV16 and HPV18, account for 70% of cases. HPV16 is responsible for almost 90% of HPV positive, oropharyngeal cancers. Between 60% and 90% of the other cancers listed above are also linked to HPV. HPV is the most common sexually transmitted infection (STI) globally. Worldwide an estimated 569,000 new cases of cervical cancer occur annually , with 311,000 deaths. Around 85% of these cervical cancers occurred in low and middle-income countries. In the United States, about 30,700 cases of cancer due to HPV occur each year.
RARE DISEASE
We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and yet to be discovered rare diseases. There are currently more than 4,000 life threatening rare diseases with no treatment, 400 million people worldwide are currently suffering from rare diseases without reliable treatment or prophylaxis. We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way allowing us to be at the forefront of patient response when it comes to rare diseases threats, affecting millions of people every year.
Haemophilus Influenza Type A Vaccine (Hia)
IVIV 378
-
Platform
Conjugation
-
Market
Hemophilus Influenza A was recognized as an important pathogen causing severe infections in young children. Remarkably, the highest incidence rates of invasive Hia disease are found in North American Indigenous populations, specifically Indigenous tribes of Navajo and Inuit. In these populations Hia has become the leading cause of bacterial meningitis among children.
- INFECTIOUS DISEASES
We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and unknown infectious diseases. We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way. Allowing us to be at the forefront of patient response when it comes to infectious disease threats, affecting millions of people every year. We currently have five prophylactic vaccines in our development pipeline
See Vaccines - IMMUNOTHERAPHY
We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and future types of cancers. We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way. Allowing us to be at the forefront of patient response when it comes to cancer treatements, affecting millions of people every year.
See Vaccines - RARE DISEASES
We believe the world needs a mix of traditional and innovative approaches in the prevention of both known and yet to be discovered rare diseases. There are currently more than 4,000 life threatening rare diseases with no treatment, 400 million people worldwide are currently suffering from rare diseases without reliable treatment or prophylaxis. We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way allowing us to be at the forefront of patient response when it comes to rare diseases threats, affecting millions of people every year.
See Vaccines
PIPELINE
Pediatric & Adolescent
Vaccines
Platform: Conjugation
Rights: Worldwide
VACCINE
DISCOVERY
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
Men ACYW135 Conjugate Vaccine
ID: IVIV 304
Platform: Conjugation
Stage: Pre-clinical
Rights: Worldwide
Pentavalent (DTaP-IPV-Hib)
ID: IVIV 521
Platform: Conjugation
Stage: Discovery
Rights: Worldwide
Hexavalent (DTaP-IPV-Hib – HepB)
ID: IVIV 859
Platform: Conjugation
Stage: Discovery
Rights: Worldwide
Haemophilus Influenza Type A Vaccine (Hia)
ID: IVIV 378
Platform: Conjugation
Stage: Phase 1
Rights: Worldwide
HPV (High Valency)
ID: IVIV 820
Platform: Conjugation
Stage: Discovery
Rights: Worldwide
Adult
Vaccines
Platform: mRNA
Rights: Worldwide
VACCINE
DISCOVERY
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
Platform: Conjugation
Rights: Confidential
VACCINE
DISCOVERY
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
mRNA Airborne Infectious Disease Vaccine
ID: IVIV 391
Platform: mRNA
Stage: Discovery
Rights: Worldwide
mRNA Airborne Infectious Disease Vaccine
ID: IVIV 399
Platform: mRNA
Stage: Discovery
Rights: Worldwide
PCV-25 Adult (Licensed Product):
ID: IVIV 433
Platform: Conjugation
Stage: Phase 1
Rights: Confidential
TECHNOLOGY PLATFORMS
CONJUGATION
Our licensed conjugation technology is designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines. Our licensed technology addresses the reduction in immunogenicity observed with other vaccines by increasing the availability of antigenic epitopes. In addition, our licensed proprietary technology increases the carrier function, and suppresses the immune response towards carriers.
OUR PROCESS
Target preparation - Capsular Polysaccharide reduction
Carrier preparation - Carrier protein activation, followed by proprietary linker attachment
Conjugation - Functionalizing the activated Polysaccharide with a linker
Conjugation complete -
Maximizing long term storage stability by means of a buffer
mRNA
Vaccine design with better LNP for delivery of mRNA to the cells.
More information coming soon.
- CONJUGATION
Our licensed conjugation technology is designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines. Our licensed technology addresses the reduction in immunogenicity observed with other vaccines by increasing the availability of antigenic epitopes. In addition, our licensed proprietary technology increases the carrier function, and suppresses the immune response towards carriers.
OUR PROCESS
Target preparation - Capsular Polysaccharide reduction
Carrier preparation - Carrier protein activation, followed by proprietary linker attachment
Conjugation - Functionalizing the activated Polysaccharide with a linker
Conjugation complete - Maximizing long term storage stability by means of a buffer
- mRNA
Vaccine design with better LNP for delivery of mRNA to the cells.
More information coming soon.